 canadian multicent azidothymidin trial azt pharmacokinet studi object pharmacokinet azidothymidin azt larg popul earli asymptomat human immunodefici viru hiv individu studi design multicent prospect descript single-dos pharmacokinet studi fast male hiv-infect homosexu year age cdc classif II iii singl oral dose azt subsequ pharmacokinet measur period azt major metabolit glucuronylazidothymidin gazt result patient smoker nonsmok hepat dysfunct normal hepat function follow paramet azt area curv auc SD microm.h maximum concentr cmax SD microm time concentr tmax SD half-lif SD correspond valu gazt auc SD microm.h cmax SD microm tmax SD SD No signific differ comparison studi site cdc classif diseas smoker nonsmok patient hepat dysfunct auc cmax azt latter group azt pharmacokinet similar patient earli asymptomat hiv diseas previou report patient later diseas